| Item 1. | |
| (a) | Name of issuer:
Lyell Immunopharma, Inc. |
| (b) | Address of issuer's principal executive offices:
201 Haskins Way, South San Francisco, California, 94080 |
| Item 2. | |
| (a) | Name of person filing:
This Schedule is filed by Innovative Cellular Therapeutics Holdings Limited, a Cayman Island exempted company incorporated with limited liability. The foregoing entity is referred to as the "Reporting Person." |
| (b) | Address or principal business office or, if none, residence:
The address for the Reporting Person is:
190 Elgin Avenue
George Town, Grand Cayman KY1-9008 |
| (c) | Citizenship:
See Row 4 of cover page for the Reporting Person. |
| (d) | Title of class of securities:
Common Stock, par value $0.0001 |
| (e) | CUSIP No.:
55083R203 |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
| (a) |  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
|
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
|
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
|
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
|
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
|
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
|
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
|
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
|
| | |
| Item 4. | Ownership |
| (a) | Amount beneficially owned:
The following information with respect to the ownership of the Common Stock of the Issuer by the person filing this Statement is provided as of November 6, 2025.
See Row 9 of cover page for the Reporting Person. |
| (b) | Percent of class:
See Row 11 of cover page for the Reporting Person. |
| (c) | Number of shares as to which the person has:
|
| | (i) Sole power to vote or to direct the vote:
See Row 5 of cover page for the Reporting Person.
|
| | (ii) Shared power to vote or to direct the vote:
See Row 6 of cover page for the Reporting Person.
|
| | (iii) Sole power to dispose or to direct the disposition of:
See Row 7 of cover page for the Reporting Person.
|
| | (iv) Shared power to dispose or to direct the disposition of:
See Row 8 of cover page for the Reporting Person.
|
| Item 5. | Ownership of 5 Percent or Less of a Class. |
| | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. |
| |
Not Applicable
|
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
| |
Not Applicable
|
| Item 8. | Identification and Classification of Members of the Group. |
| |
Not Applicable
|
| Item 9. | Notice of Dissolution of Group. |
| |
Not Applicable
|
Rule 13d-1(c)